JOHANNESBURG - JSE-listed Aspen Pharmacare has reported robust financial results for the year that ended on 30 June.
READ: GNU | JSE: Political certainty crucial for capital flow
The group saw revenue increase by 10-percent.
Aspen’s chief financial officer, Sean Capazorio discussed this with eNCA.